Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting results this Thursday afternoon. Here’s what investors should know.

Amphastar Pharmaceuticals missed analysts’ revenue expectations by 1% last quarter, reporting revenues of $174.4 million, down 4.4% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates but a slight miss of analysts’ revenue estimates.

Is Amphastar Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Amphastar Pharmaceuticals’s revenue to decline 3.5% year on year to $184.5 million, a reversal from the 5.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.83 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Amphastar Pharmaceuticals has missed Wall Street’s revenue estimates five times over the last two years.

Looking at Amphastar Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 11.7%, beating analysts’ expectations by 2.1%, and Eli Lilly reported revenues up 53.9%, topping estimates by 9.6%. Amneal traded up 3.7% following the results while Eli Lilly was also up 6%.

Read our full analysis of Amneal’s results here and Eli Lilly’s results here.

Investors in the pharmaceuticals segment have had steady hands going into earnings, with share prices flat over the last month. Amphastar Pharmaceuticals is down 5.2% during the same time and is heading into earnings with an average analyst price target of $32.50 (compared to the current share price of $25.21).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.